73 related articles for article (PubMed ID: 3348637)
1. [A clinical trial to prevent the renal toxicity of cisplatin by administration of bismuth subnitrate].
Taniwaki M; Yokota S; Nishida K; Tsuda S; Edagawa J; Misawa S; Takino T; Abe T
Gan To Kagaku Ryoho; 1988 Mar; 15(3):531-3. PubMed ID: 3348637
[No Abstract] [Full Text] [Related]
2. [Prevention of renal toxicity of cisplatin by administration of bismuth subnitrate].
Hamada T; Nishiwaki Y; Kodama T; Hayashibe A; Nukariya N; Sasaki H; Morikawa T; Hirosawa T; Matsuyama T
Gan To Kagaku Ryoho; 1989 Nov; 16(11):3587-93. PubMed ID: 2554815
[TBL] [Abstract][Full Text] [Related]
3. [Alleviation of cisplatin toxicity by high-dose bismuth subnitrate and pharmacokinetics of bismuth subnitrate and cisplatin].
Morikawa T; Kawamura E; Komiyama T; Imura N
Nihon Gan Chiryo Gakkai Shi; 1990 Jun; 25(6):1138-45. PubMed ID: 2398299
[TBL] [Abstract][Full Text] [Related]
4. [The effect of bismuth subnitrate on cisplatin toxicity].
Chen JT; Kurokawa Y; Nakayama K; Saito K; Sakamoto K; Fukuda K; Hirai Y; Hamada T; Fujimoto I; Yamauchi K
Nihon Sanka Fujinka Gakkai Zasshi; 1987 May; 39(5):815-22. PubMed ID: 3298471
[TBL] [Abstract][Full Text] [Related]
5. [The pharmacokinetics of cisplatin and its influence on renal function according to different infusion methods (report II)--alleviation of renal impairment by bismuth subnitrate combined with ginseng and tang-koui ten].
Takahashi A; Takagi M; Hishida H; Sakamoto Y; Takagi N; Amano H; Ogura Y
Gan To Kagaku Ryoho; 1989 Jul; 16(7):2405-10. PubMed ID: 2665654
[TBL] [Abstract][Full Text] [Related]
6. A dose-seeking trial of edatrexate in combination with vinblastine, adriamycin, cisplatin, and filgrastim (EVAC/G-CSF) in patients with advanced malignancies: promising antineoplastic activity against non-small cell lung carcinomas.
Colón-Otero G; Marschke R; Camoriano JK; Sorensen JM; Sloan JA; Richardson RL
Cancer J Sci Am; 1997; 3(5):297-302. PubMed ID: 9327154
[TBL] [Abstract][Full Text] [Related]
7. [Effect of bismuth subnitrate on renal disorder after lipiodol-cisplatinum arterial infusion chemotherapy (first report)].
Ohsumi M; Iijima T; Koitabashi H; Nagamachi Y
Gan To Kagaku Ryoho; 1991 Jan; 18(1):131-4. PubMed ID: 1846281
[No Abstract] [Full Text] [Related]
8. Prevention of lethal and renal toxicity of cis-diamminedichloroplatinum(II) by induction of metallothionein synthesis without compromising its antitumor activity in mice.
Naganuma A; Satoh M; Imura N
Cancer Res; 1987 Feb; 47(4):983-7. PubMed ID: 3802104
[TBL] [Abstract][Full Text] [Related]
9. [An early phase II trial combining cisplatin and carboplatin in advanced non-small cell lung cancer].
Yoshimura A; Yamano Y; Gemma A; Yoshimori K; Hayashihara K; Taniguchi Y; Uematsu K; Shibuya M; Kudoh S; Niitani H
Gan To Kagaku Ryoho; 1993 Mar; 20(4):503-8. PubMed ID: 8383951
[TBL] [Abstract][Full Text] [Related]
10. Citrate enhances the protective effect of orally administered bismuth subnitrate against the nephrotoxicity of cis-diamminedichloroplatinum.
Kondo Y; Himeno S; Satoh M; Naganuma A; Nishimura T; Imura N
Cancer Chemother Pharmacol; 2004 Jan; 53(1):33-8. PubMed ID: 14530870
[TBL] [Abstract][Full Text] [Related]
11. High-dose cisplatin with fluid and mannitol-induced diuresis in advanced lung cancer: a phase II clinical trial of the EORTC Lung Cancer Working Party (Belgium).
De Jager R; Longeval E; Klastersky J
Cancer Treat Rep; 1980; 64(12):1341-6. PubMed ID: 6258791
[TBL] [Abstract][Full Text] [Related]
12. [Randomized control study of methylprednisolone in the prevention of CDDP-induced emesis].
Funaki Y; Sawamura N; Takahashi S; Yoshioka T; Yokoyama S; Saijo N; Suemasu K
Gan To Kagaku Ryoho; 1984 Sep; 11(9):1880-2. PubMed ID: 6383220
[TBL] [Abstract][Full Text] [Related]
13. [A randomized trial of Zudan in the prophylaxis of nausea and vomiting induced by cisplatin].
Huang J; Wang Z; Zhou L
Zhonghua Zhong Liu Za Zhi; 1998 Mar; 20(2):153-4. PubMed ID: 10920971
[TBL] [Abstract][Full Text] [Related]
14. Phase I clinical evaluation of cytarabine and cisplatin in patients with advanced cancer.
Schilsky RL; Muscato JJ; Muscato MS; Perry MC
Cancer Treat Rep; 1984 Sep; 68(9):1097-102. PubMed ID: 6541094
[TBL] [Abstract][Full Text] [Related]
15. [Intraperitoneal cisplatin in peritoneal carcinomatosis patients].
Toi M; Shiramizu T; Yonemura T; Ezaki T; Oka N; Yoshida T; Tsurumaru H
Gan No Rinsho; 1985 May; 31(5):522-6. PubMed ID: 4040582
[TBL] [Abstract][Full Text] [Related]
16. [Clinical evaluation of 2 mg granisetron tablet for nausea and vomiting induced by anticancer drugs including cisplatin].
Takada M; Furuse K; Fukuoka M; Kawahara M; Negoro S; Kusunoki Y; Ogawara M; Furue H
Gan To Kagaku Ryoho; 1997 Jun; 24(8):987-94. PubMed ID: 9212809
[TBL] [Abstract][Full Text] [Related]
17. Phase II trial of cisplatin in small cell carcinoma of the lung.
Levenson RM; Ihde DC; Huberman MS; Cohen MH; Bunn PA; Minna JD
Cancer Treat Rep; 1981; 65(9-10):905-7. PubMed ID: 6268297
[TBL] [Abstract][Full Text] [Related]
18. Phase II study of uracil-tegafur plus cisplatin in patients with previously untreated advanced non-small cell lung cancer.
Takayama K; Kawasaki M; Ninomiya K; Motohiro A; Fujita M; Watanabe K; Kajiki A; Iwami F; Miyazaki N; Izumi M; Hara N; Nakanishi Y;
Respirology; 2008 Jan; 13(1):103-7. PubMed ID: 18197918
[TBL] [Abstract][Full Text] [Related]
19. Phase I trial of cisplatin in combination with glutathione.
Plaxe S; Freddo J; Kim S; Kirmani S; McClay E; Christen R; Braly P; Howell S
Gynecol Oncol; 1994 Oct; 55(1):82-6. PubMed ID: 7959273
[TBL] [Abstract][Full Text] [Related]
20. [Role of metallothionein in cancer chemotherapy].
Naganuma A; Imura N
Gan To Kagaku Ryoho; 1994 Feb; 21(3):301-6. PubMed ID: 8109985
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
